Well, these patients are at end of their treatment journey; other options have been exhausted. From the inclusion criteria here: https://clinicaltrials.gov/ct2/show/NCT04876651
Should have received one line of prior taxane therapy or have refused or be ineligible for taxanes
Once a patient stops responding to Cabazitaxel there is no point continuing it. And it's rarely curative.
Also, side effects from chemo are horrible. Really terrible. So you wouldn't want any adverse events from chemo being ascribed to TLX591.
Problem with ProstACT Clinical Trial, page-4
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.44 |
Change
-0.320(1.54%) |
Mkt cap ! $6.840B | |||
| Open | High | Low | Value | Volume |
| $20.79 | $21.00 | $20.22 | $19.41M | 945.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $20.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.46 | 45 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| TLX (ASX) Chart |